StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Internal-use software amortization expense by Year

Internal-use software amortization expense ($M) ($M)

Vertex Pharmaceuticals Internal-use software amortization expense: $31.2M in FY2025, up 23.8% from a year earlier.

Latest, FY2025
31.2
Period ended Dec 31, 2025
Change on a year earlier
+23.8%
25.2 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-K Note (Property and Equipment).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInternal-use software amortization expense ($M) ($M)Year on yearSource
FY2025Dec 31, 202531.2+23.8%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 202425.2+113.6%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 202311.8–Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 20220–Form 10-K (filed 2025-02-13) ↗
FY2021Dec 31, 20210–Form 10-K (filed 2024-02-15) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Internal-use software amortization expense ($M), annual FY2021–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/software-amort

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.